baber/WOPTO huggingface dataset:
Patent NZ-235564-A (NZ)
Title: Fibrinogen receptor antagonist and pharmaceutical compositions
Inventor: NUTT RUTH F
IPC: C07K7/06
Filed: 1990-10-04
Abstract: A fibrinogen receptor antagonist of the formula <CHEM> wherein XX represents a synthetic alpha-amino acid containing a phenyl or C3-C8 cycloalkyl group, and ZZ represents a sequence of 1, 2, 3 or 4 amino acids.
Patent NZ-243130-A (NZ)
Title: Preparation of free-flowing spray-dried particulate detergent by
Inventor: CUSH JAMES FRANK
IPC: C11D3/33
Filed: 1992-06-12
Abstract: A process for producing a free-flowing, zeolite-containing spray-dried particulate detergent composition is described, said detergent composition having improved particle mechanical strength and integrity concomitant with high solubility characteristics such that the amount of visible residue deposited on fabrics laundered with such detergent composition is significantly minimized comprising the steps of:   (a) forming an aqueous crutcher slurry containing (i) at least about 5%, by weight, of a zeolite; (ii) an effective amount of a defined bead strengthening agent; and (iii) from about 0 to 50%, by weight, of a supplementary detergent builder; said crutcher slurry being essentially free of sodium silicate and bentonite and containing less than about 3%, by weight, of anionic and/or nonionic surface active detergent compounds, all percentages being based on the solids content of the slurry, in the absence of water; (b) spray-drying the crutcher slurry of step (a) to produce spray-dried particles; and (c) applying one or more anionic, nonionic and/or cationic surface active detergent compounds to the spray-dried particles. d
Patent NZ-244108-A (NZ)
Title: Herbicides comprising a phosphonate or phosphinate and one or more of phenmedipham, desmedipham, metamitron, lenacil, ethofumesate and chloridazon
Inventor: RUSCH REINHART
IPC: A01N43/48
Filed: 1992-08-27
Abstract: A herbicidal composition which comprises a phosphonate or phosphinate of formula (I), where R and R', which may be the same or different, each represent straight or branch-chained alkyl of 1 to 12 carbon atoms, and x and y are each 1 or 2, the sum of x and y being 3; and phenmedipham, desmedipham, metamitron, lenacil, ethofumesate or chloridazon in association with a suitable carrier and/or surface active agent, and a method of combating weeds.
Patent NZ-258533-A (NZ)
Title: Vinyl ester and amide derivatives of a dicarboxylic acid cyclic-oligomeric carbohydrate half ester; use for forming contact lenses, as thickeners, surfactants and lens cleaning agents
Inventor: VETTER DIRK
IPC: G02B1/04
Filed: 1993-11-19
Abstract: PCT No. PCT/EP93/03236 Sec. 371 Date Jul. 26, 1994 Sec. 102(e) Date Jul. 26, 1994 PCT Filed Nov. 19, 1993 PCT Pub. No. WO94/12540 PCT Pub. Date Jun. 9, 1994.Compounds of formulae I and Ia R-Y-CO-R3-CO-O-A(I), R-Y-CO-R3-CO-O-CH2-A1(Ia), wherein R is a radically polymerisable hydrocarbon group, R3 is a direct bond, linear or branched C1-C22alkylene, C3-C8cycloalkylene or C6-C14arylene, A is the radical, reduced by a hydroxy group in a 2- or 3position, of a cyclic-oligomeric carbohydrate or of a derivative of such a carbohydrate, A1 is the radical, reduced by a hydroxymethyl group, of a monomeric or linear oligomeric carbohydrate or of a derivative of such a carbohydrate, and Y is -O-, -NH- or -N(C1-C6alkyl)-. Homo- and co-polymers having those monomers have, depending upon their composition, hydrophilic, amphiphilic or hydrophobic properties and are able to form hydrogels. The polymers can be used, for example, as surfactants, thickeners, carriers for biologically active ingredients or in the manufacture of contact lenses.
Patent NZ-265292-A (NZ)
Title: Oven and associated processing equipment for heating epoxy resin above its gelation temperature with decoupled electromagnetic heating units
Inventor: MALLAH MOHAMAD
IPC: H05B6/70
Filed: 1994-04-25
Abstract: PCT No. PCT/EP94/01275 Sec. 371 Date Jan. 30, 1995 Sec. 102(e) Date Jan. 30, 1995 PCT Filed Apr. 25, 1994 PCT Pub. No. WO94/26077 PCT Pub. Date Nov. 10, 1994The present invention relates to a process for the manufacture of castings from an essentially liquid reactive medium as casting material which, above its gelation temperature, reacts to form a solid material. The liquid reactive medium is fed from a supply tank, in which the temperature of the casting material lies substantially below its gelation temperature. The liquid reactive medium is fed into a casting mould which has been heated to a temperature that lies above the gelation temperature of the casting material. The casting material is substantially preheated directly before it enters the casting mold to a temperature close to but below the gelation temperature of the casting material.
Patent NZ-274694-A (NZ)
Title: Androst-16-en-3-ol derivatives having a (thi)azacycloalkyl group substituted by amino at c-17 or by unsubstituted pyrrole, thienyl or furanyl
Inventor: PEET NORTON PAUL
IPC: C07J43/00
Filed: 1994-09-29
Abstract: The present invention relates to  DELTA 16 unsaturated steroids which are useful as steroid C17-20 lyase inhibitors.
Patent NZ-311842-A (NZ)
Title: A process for the optical purification of enantiomerically enriched benzimidazole derivatives
Inventor: UNGE SVERKER VON
IPC: C07D401/12
Filed: 1996-06-26
Abstract: Process for the optical purification of the single enantiomers of some 2-sulphinyl-1H-benzimidazole derivatives and another structurally related sulphoxide from the respective enantiomerically enriched preparation thereof.
Patent NZ-325529-A (NZ)
Title: Low moisture, triglyceride fat-free corn snack food product
Inventor: JENSEN JOHN MICHAEL
IPC: A23L19/18
Filed: 1996-05-30
Abstract: A process for preparing digestible fat-free corn chips comprises: a) preparing raw corn chip pieces from an aqueous dough comprising from about 50 parts to about 70 parts of a mixture of corn and a fat-free filler selected from the group consisting of starch, protein and nondigestible fiber, and mixtures thereof; and b) cooking said raw corn chip pieces in nondigestible fat at 300  F to 450  F (148.9  C to 232  C.  The corn snacks comprise from about 20 % to 45 % corn, 20 % to about 50 % fat-free filler, 23 % to 35 % nondigestible fat, from 0 % to about 4 % moisture, and from 0 % to 10 % of other essentially fat-free ingredients.  The fat free filler may be a starch, a nondigestible fibre or protein or equal amounts thereof.
Patent NZ-328042-A (NZ)
Title: preparation of 5-(alkoxymethyl)-2,3-pyridinedicarboximides; intermediates
Inventor: KREMER KENNETH ALFRED MARTIN
IPC: C07D401/04
Filed: 1997-06-09
Abstract: What is claimed is a process for making a preparation of a 5-(alkoxymethyl)-2,3-pyridinedicarboximide compound, where the variables are as described in the specification.  The process comprises reacting an oxime of  2-alkoxymethyl-2-propen-1-one with a substituted maleimide compound in the presence of an alkali metal acetate and a solvent at elevated temperature.
Patent NZ-330889-A (NZ)
Title: Cycloalkyl substituted imidazoles and their use in treating CSB/RK/p38 kinase mediated diseases
Inventor: ADAMS JERRY L
IPC: A61K31/00
Filed: 1997-01-10
Abstract: Disclosed are 1,4,5- substituted imidazole compounds of formula (I) and compositions for use in treating CSB/RK/p38 kinase mediated diseases.
Patent NZ-331813-A (NZ)
Title: Benzothiepine compounds having activity as inhibitors of ileal bile acid transport and taurocholate uptake
Inventor: REITZ DAVID B
IPC: C07D409/10
Filed: 1997-03-11
Abstract: A benzothiepine compound has the formula (I) wherein: q is 1 to 4 and n is 0 to 2; R1 and R2 are independently H or optionally substituted alkyl, alkenyl, alkynyl, haloalkyl, alkylaryl, arylalkyl, alkoxy, alkoxyalkyl, dialkylamino, alkylthio, (polyalkyl)aryl or cycloalkyl which can optionally have one or more carbons replaced by O, NR9, N+R9R10A-, S, SO, SO2, S+R9A-, P+R9R10A-, or phenylene or R1 and R2 taken together with the carbon to which they are attached form a cycloalkylidene; R3 and R4 are H, alkyl, alkenyl, alkynyl, acyloxy, aryl, heterocycle, OR9, NR9R10, SR9, S(O)R9, SO2R9, or SO3R9 or R3 and R4 together form =O, =NOR11, =S, =NNR11R12, NR9, or =CR11R12; R5 and R6 are independently H or optionally substituted  alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, quaternary heterocycle, OR9, SR9, S(O)R9, SO2R9  or SO3R9; A is a pharmaceutically acceptable anion and M is pharmaceutically acceptable cation; R7 and R8 are independently hydrogen or alkyl; each Rx are independently H or halogen or optionally substituted alkyl, alkenyl, alkynyl, polyalkyl, acyloxy, aryl, arylalkyl, haloalkyl, cycloalkyl, heterocycle, heteroaryl, polyether, quaternary heterocycle, quaternary heteroaryl, OR13, NR13R14, SR13, S(O)R13, S(O)2R13, SO3R13, S+R13R14A-, NR13OR14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, NR14C(O)R13, C(O)NR13R14, NR14C(O)R13, C(O)OM, COR13, OR18, S(O)nNR18, NR13R18, NR18OR14, N+R9R11R12A-, P+R9R11R12A-, amino acid, peptide, polypeptide, or carbohydrate; and wherein in Rx, one or more carbons are optionally replaced by O, NR13, N+R13R14A-, S, SO, SO2, S+R13A-, PR13, P(O)R13, P+R13R14A-, phenylene, amino acid, peptide, polypeptide, carbohydrate, polyether, or polyalkyl; wherein in the polyalkyl, phenylene, amino acid, peptide, polypeptide, and carbohydrate, one or more carbons are optionally replaced by O, NR9, N+R9R10A-, S, SO, SO2, S+R9A-, PR9, P+R9R10A- or P(O)R9; R9 to R14 and R18 are as defined in the complete specification; provided that i) both R5 and R6 cannot be OH, or SH; ii) when R5 is OH, R1, R2, R3, R4, R7 and R8 cannot be all hydrogen; iii) when R5 or R6 is phenyl, only one of R1 or R2 is H; iv) when q is 1 and Rx is styryl, anilido, or anilinocarbonyl, only one of R5 or R6 is alkyl and v) R5 or R6 can not be hydroxy. Also disclosed is a compound of formula (I) wherein R5 is a group of spacer-B wherein B is a group of formula (I) and the spacer is either -phenylene-R19-phenylene or -R19- wherein R19 is as defined in the complete specification. A pharmaceutical composition thereof is useful for the prophylaxis or treatment of a hyperlipidemic condition, an atherosclerotic condition or hypercholerterolemia.
Patent NZ-332803-A (NZ)
Title: Metalloproteinase inhibitors, a process for their preparation and compositions containing them for inhibiting degradation of cell tissue eg in rheumatoid arthritis
Inventor: DE NANTEUIL GUILLAUME
IPC: A61P9/10
Filed: 1998-11-13
Abstract: Tetrahydro carboline derivatives of formula (I) and their preparation from D-tryptophan derivatives. Tetrahydrocarboline derivatives of formula (I) their isomers and their salts m = 1, 2,3, or 4; n and p = 0, 1, 2, 3, or 4; X = O, S, or a simple bond; R1 = H, halogen, 1-6C alkyl or trihaloalkyl, OH, 1-6C alkoxy or trihaloalkoxy; R2, R3, and R4 = H or 1-6C alkyl; R5 = H, halogen,1-6C alkoxy, aryloxy or heteroaryloxy; R6, R7, and R8 = H, 1-6C alkyl, or R6 with N and R7 or R8 form a heterocycle; R9 = -SO3H, -COOR10, -CO-NR11R12, or -NR13R14; R10 = H or 1-6C alkyl; R11 and R12 = H or 1-6C alkyl or form an optionally substituted heterocycle with the N atom; R13 and R14 = H or 1-6C alkyl or form an optionally substituted heterocycle with the N atom
Patent NZ-501359-A (NZ)
Title: Non-steroidal(hetero) cyclically substituted acylanilides with mixed gestagen and androgen activity
Inventor: LEHMANN MANFRED
IPC: C07D265/02
Filed: 1998-06-02
Abstract: Non-steroidal gestagen compounds of formula (I) where: R1 and R2 are the same or different and are selected from hydrogen, C1-C5 alkyl, halogen, or together with the C-atom of the chain form a ring with a total of 3-7 links; R3 is a C1-C5 alkyl or a partially or completely fluorinated C1-C5 alkyl; A is an optionally substituted mono or bi-cyclic aromatic ring, an ester group -COOR4, an alkenyl group -CR5=CR6R7, an alkinyl group -C=CR5 or for a partially or fully fluorinated C1-C5 alkyl group, B is a carbonyl group of CH2 group; Ar is a ring system selected from formula 2-11 in which radicals X3a, X4, X6, X7 (formula 2), X4, X6, X7 (formula 3 and 4), X3a, X3b, X4, X6, X7, (formula 5, 6 and 7) or Y4, Y5, Y7, Y8 (in formula 8, 9, 10 and 11) are the same or different and are selected from hydrogen, C1-C5 alkyl, which in addition can contain a hydroxy group optionally etherified with a C1-C5 alkyl or esterified with a C1-C5 alkanoyl, partially or completely fluorinated C1-C5 alkyl, C2-C5 alkenyl -CR5=CR6R7, alkinyl -CºCR5 (where R5, R6 and R7 are as defined), radicals X3a and X3b  also together with the C-atom of benzocondensed ring system 5, 6 or 7 can form a ring with a total of 3-7 links, and radicals X4, X6, X7 (formula 2, 3, 4, 5, 6 and 7) or Y4, Y5, Y7, Y8 (in formula 8, 9, 10 and 11) are selected from halogen, hydroxy, C1-C5 alkoxy or C1-C5 alkanoyloxy, and if B is a CH2, the physiologically compatible salts of the compounds of formula (I) with acids. The compounds display a very strong affinity to the gestagen receptor. They can be used on their own or in combination with oestrogen's in contraceptive preparations. They can also be used in the treatment of endometriosis or with oestrogen's in preparations for the treatment of gynaecological disorders. They can also be used to treat pre-menstrual complaints and in substitution therapy. Their androgen activity enables them to be used for male fertility control, male HRT and to treat andrological syndromes.
Patent NZ-502364-A (NZ)
Title: Arrangement for controlling an angularly movable member
Inventor: MOORE DAVID
IPC: E05F3/16
Filed: 1998-06-17
Abstract: A control mechanism for use with a door closer comprises of a shaft (10), angularly movable between a normal position or first position (21a) and a second position (21b).  A biasing means is attached to the shaft first portion for returning the shaft to the normal position (21a) from the second position (21b).    A damping mechanism (36, 38), attached to the shaft second portion, resists the movement of the shaft from the second position to the normal position.  The damping mechanism includes a fluid chamber containing a non-pressurized damping medium, and a coiled strap-like member (36) is disposed within the fluid chamber.
Patent NZ-502739-A (NZ)
Title: 4-cyano-4-deformylsordaricin derivatives and their use as antifungal agents
Inventor: TSE BRUNO
IPC: C07C255/47
Filed: 1998-08-18
Abstract: 4-Cyano-4-deformylsordaricin derivatives having the formula I, wherein: R is C(=O)OR1, C(=O)NR2R3, C(=O)R4, CH(R2)OR5, C(R6)(R7)(R8), formula 2 or H; R1 is C1-C14 alkyl, C2-C14 alkenyl, C2-C14 alkynyl, C3-C20 cycloalkyl, aryl or aryl C1-6 alkyl; R2 and R3 are independently H or R1; R4 is H, R1 or -(CH2)mNR2R3; R5 is R1 or  -(CH2)xO(CH2)yH; R6 is H, Cl-Cl4 alkyl, aryl, aryl C1-6 alkyl, -(CH2)yCHR9(CH2)zH, -(CH2)yCºC(CH2)zH, -(CH2)yC(R7)=CH(CH2)zH, -(CH2)yCºC(CH2)mR9, -(CH2)yC(R7)=CH(CH2)mR9; R7 and R8 are independently H or C1-C14 alkyl; R9 is OH or NR2R3; R10 is H, -CH2C6H5, -CH2CH=CH2, formula 3, formula 4, formula 5, formula 6 or formula 7; n is 0 or 1; m 1-6; x is 2-6; y is 0-6; z is 0-6; or a pharmaceutically or agriculturally acceptable salt thereof. The compounds are antifungal agents useful in the treatment and/or prevention of human and animal fungal infections, as well as in the control of phytopathogenic fungi in crops.
Patent NZ-503401-A (NZ)
Title: Use of interferon-beta (IFN-B) genes for the treatment of cancer
Inventor: QIN XIAO-QIANG
IPC: C12N7/00
Filed: 1998-08-25
Abstract: Described is an exvivo cell system for use in vivo expression of an interferon-beta protein, the system comprising: a cell of a mammal; and a vector contained therein having an interferon beta polynucleotide sequence for encoding interferon beta protein and allowing its expression.
Patent NZ-508622-A (NZ)
Title: Epothilone derivatives and their synthesis and use
Inventor: NICOLAOU KYRIACOS
IPC: C07D303/00
Filed: 1999-06-21
Abstract: Methods of producing Epothilone analogues with side chain modifications and the use of said analogues in the treatment of proliferative disease and in the manufacture of pharmaceuticals.  Also covered are the analogues themselves, and novel intermediates used in the synthesis of the analogues.
Patent NZ-509327-A (NZ)
Title: Alpha-amino acid phenyl ester derivatives for use in general anaesthesia
Inventor: HAMILTON NIALL MORTON
IPC: C07B57/00
Filed: 1999-07-16
Abstract: a-amino acid phenyl ester derivatives of formula (I) are disclosed, wherein: R1 is (C1-3) alkyloxy; R2 is (C1-3)alkyl, (C1-3)alkyloxy or (C2-3)alkenyl; R3 is hydrogen, (C1-3)alkyl, (C1-3)alkyloxy or (C2-3)alkenyl; R4 is (C1-6)alkyl; R5 and R6 are independently (C1-6)alkyl, (C2-6)alkenyl, (C2-6)alkynyl or aralkyl, each of which may be optionally substituted with (C1-3)alkyloxy, (C1-3)alkyloxycarbonyl, cyano or NR7R8; R7 and R8 are independently (C1-6)alkyl, with the exclusion of 2,6-dimethoxyphenyl 2-(diethylamino)propionate and 2,6-dimethoxyphenyl 2-(diethylamino)butyrate. Pharmaceutical compositions comprising these derivatives of formula (I), and the use of these a-amino acid phenyl ester derivatives as hypnotics for the induction and maintenance of general anaesthesia are also disclosed.
Patent NZ-512141-A (NZ)
Title: Method of packaging solvent or water based formulations to reduce skinning where a anti skinning layer is located on at least a portion of an internal surface of a container or seal
Inventor: VAN DYK ANTONY KEITH
IPC: B65D43/02
Filed: 1999-11-10
Abstract: The packaging relates to packaging water or solvent-based formulations, in particular to those formulations that are prone to skinning. The packaging comprises a container (1) that is adapted to contain such a formulation (4) in which an anti-skinning layer (6) is located between at least a portion of an internal surface of the container (1) or a lid (5) and the formulation (4).
Patent NZ-514697-A (NZ)
Title: Substituted benzolactam compounds
Inventor: SOBOLOV-JAYNES SUSAN BETH
IPC: A61K31/4709
Filed: 2000-04-13
Abstract: Substituted benzolactam and cyclic thioamide compounds of formula (I) useful in the manufacture of a medicament for treating gastrointestinal disorders, central nervous system (CNS) disorders, inflammatory diseases, emesis, urinary incontinence, pain, migraine, angiogenesis or the like, especially CNS disorders in a mammalian subject, especially humans.
Patent NZ-516734-A (NZ)
Title: A trapezoid wall block with upper lips and a lower base as interlocking features stacked vertically for the creation of arcurate, curved and/or sinusoidal retaining walls
Inventor: BOTT TIMOTHY A
IPC: E04C1/39
Filed: 2002-01-22
Abstract: A wall block arranged to be stacked vertically for creation of a retaining wall, the block being of generally trapezoidal configuration having parallelly arranged front and rear surfaces along with opposed top and bottom surfaces is described.  The top surface has front and rear lips formed thereon with each of the lips having a trapezoidal root portion with mutually opposed triangular portions converging inwardly therefrom to define opposed and aligned front and rear apices.  In one embodiment, the apices are disposed midway along the length of the block, while in a second embodiment, the apices are formed at the juncture point of mated pairs of blocks.  The bottom surface of the block includes a central base with opposed notches formed along the front and rear edges of the bottom surface, with the base having a trapezoidal configuration with a width dimension which is no greater than the spacing between the opposed aligned front and rear apices. The figure shows a top plan view of a retaining wall in sinusoidal configuration utilizing the block described.
Patent NZ-520300-A (NZ)
Title: Morpholino-substituted pyridopyrimidine, quinolone and benzopyranone derivatives that inhibit the enzyme phosphoinositide (PI) 3-kinase
Inventor: ROBERTSON ALAN D
IPC: C07D311/22
Filed: 2001-01-24
Abstract: Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives that inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes are disclosed. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. These compounds are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. These compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.
Patent NZ-520713-A (NZ)
Title: Method for producing aryl-iminomethyl-carbamic acid esters
Inventor: BRANDENBURG JOERG
IPC: C07C271/64
Filed: 2001-01-11
Abstract: The process for preparing aryl-iminomethyl-cabamic acids esters of formula I (see below) are described. The intermediate products formed throughout the process are disclosed as is the uses of these intermediates.
Patent NZ-522327-A (NZ)
Title: Mammalian DNAX Toll-like receptor protein, DTLR 10, antibodies and medicaments made therefrom and use in treating immunological disorders
Inventor: HARDIMAN GERARD T
IPC: C12Q1/02
Filed: 2001-05-23
Abstract: Described are nucleic acids encoding mammalian DNAX Toll-like receptor DTLR10, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, methods of using the compositions made therefrom for both diagnostic and therapeutic uses are also provided.
Patent NZ-524481-A (NZ)
Title: Expandable laser catheter with optical fibers attached to fins
Inventor: WINSTON THOMAS R
IPC: A61F2/958
Filed: 1999-07-29
Abstract: Flexible shafting 62 has fins 66A,66B to which are attached ends of optical fibers (not shown). The other ends of the fibers are typically connected to a laser (not shown). (62) Divided out of 509916
Patent NZ-525753-A (NZ)
Title: HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
Inventor: SOERENSEN BIRGER
IPC: G01N33/569
Filed: 2000-03-02
Abstract: Peptides based on conserved regions of a human immunodeficiency virus (HIV) protein capable of inducing an HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV are disclosed. Such peptides are useful as vaccines and for detecting antibodies induced by the HIV in a sample and are based on conserved regions of HIV gag p24 proteins. Antigens in free- or carrier-bound form comprising at least one of the said peptides, vaccine compositions containing at least one of the antigens, immunoassay kits and a method of detecting antibodies induced by HIV or HIV specific peptides using such antigens, are described. (62) Divided out of 514619
Patent NZ-528167-A (NZ)
Title: Nicotine-containing oral dosage form
Inventor: LIU JOHN
IPC: A61K47/02
Filed: 2002-03-22
Abstract: Disclosed herein is a solid, oral dosage form useful for transmucosal oral administration of a nicotine active, comprising: (a) a glassy matrix base component comprising at least one substantially non-hygroscopic sugar alcohol capable of forming a glassy structure; and (b) a nicotine active from 0.5 mg to 5 mg per dosage unit, and wherein the dosage form is orally dissolvable; and wherein the amount of nicotine active is effective to reduce nicotine cravings.